Role of leukotrienes in asthma pathophysiology

Pediatric Pulmonology

Volumn 30, Issue 2, 2000, Pages 166-176

  Britto, Maria T ^a,d   Garrett, Joanne M ^b   Konrad, Thomas R ^b   Majure, J Marc ^c   Leigh, Margaret W ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DUKE UNIVERSITY   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Asthma; Cysteinyl leukotriene; Cysteinyl leukotriene receptor antagonists; Inflammation; Montelukast

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; CORTICOSTEROID; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE; MONTELUKAST; PEPTIDOLEUKOTRIENE; SLOW REACTING SUBSTANCE; ZAFIRLUKAST;

ARTICLE; ASTHMA; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; EDEMA; ENZYME ACTIVITY; ENZYME INHIBITION; EOSINOPHILIA; HUMAN; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; BRONCHIAL HYPERREACTIVITY; CYSTEINE; HUMAN; INFLAMMATION MEDIATORS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; RECEPTORS, LEUKOTRIENE;

EID: 0033855384     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-0496(200008)30:2<166::AID-PPUL15>3.0.CO;2-L     Document Type: Article

References (119)

1. Asthma
2. Pathology of asthma and its clinical implications
3. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks
4. Inflammation and repair
5. Eicosanoids and asthma: An update
6. 4 synthase activities
7. Identification and isolation of a membrane protein necessary for leukotriene production
8. Leukotriene receptor antagonists and biosynthesis inhibitors: Potential breakthrough in asthma therapy
9. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects
10. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis
11. The formation of lysocithin and of a muscle-stimulating substance by snake venoms
12. Liberation of histamine and formation of lysocithin-like substances by cobra venom
13. The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock
14. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation
15. 4
16. Nonimmunological production of leukotrienes induced by plate-let- activating factor
17. Generation of leukotrienes by human monocytes pretreated with cytochalasin B and stimulated with formyl-methionyl-leucyl-phenylalanine
18. Release of leukotrienes from guinea pig stimulated by C5(des Arg) anaphylatoxin
19. ++ ionophore A23187, from human lung parenchyma in vitro
20. Increased in vitro cysteinyl leukotriene release from blood leukocytes in patients with asthma, nasal polyps, and aspirin intolerance
21. 4 plasma levels in adult asthmatic patients with variable disease severity
22. 2 in patients with spontaneous asthma attacks
23. Persistent increase in plasma and urinary leukotrienes after acute asthma
24. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist
25. 4 in the assessment of nocturnal asthma
26. 4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma
27. 4 excretion
28. 4
29. 4 receptor
30. 4 receptor antagonist
31. Leukotriene- and histaine-induced increases in vascular permeability and interstitial transport in the skin
32. 4 in human skin
33. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans
34. Role of plasma exudation in asthmatic airways
35. Plasma exudation and asthma
36. New concepts about the mast cell
37. 4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal anti-body
38. 4 and methacholine on sputum cell differentials in asthma
39. Leukotriene E4 and granulocytic infiltration into asthmatic airways
40. 4 effects on human eosinophil and neutrophil motility in vitro
41. The effect of leukotriene B4, leukotriene C4, zymosan activated serum, histamine, tabanid extract and N-formyl-methionyl-leucyl-phenylalanine on the in vitro migration of equine eosinophils
42. Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products
43. Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence
44. Inhibition by the LTD4 antagonist, SR2640, of effects of LTD4 on canine polymorphonuclear leukocyte functions
45. 4 can stimulate human endothelial cells to synthesize platelet-activating factor and blind neutrophils
46. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro
47. 4 inhalation in normal human lung
48. 4 and histamine in exogenous asthma
49. 4 and to methacholine in patients with asthma and normal controls
50. 4, methacholine and histamine in normal and asthmatic subjects
51. 4 in the airways between patients with atopic and nonatopic asthma
52. Actions of inhaled leukotrienes and their interactions with other allergic mediators
53. 4, methacholine, and histamine
54. Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: A possible role in myointimal hyperplasia
55. Leukotriene D4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis
56. Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi
57. 4 on the airway responsiveness to histamine in subjects with asthma and normal subjects
58. 4 and histamine on bronchomotor tone
59. 4 enhance histamine responsiveness in asthmatic airways
60. 4 on glycoprotein and Iysozyme secretion by human bronchial mucosa
61. 4, increase the release of mucus from human airways in vitro
62. Leukotriene D4 (LTD4) induces mucus secretion from goblet cells in guinea pig respiratory epithelium
63. Leukotriene-C4 enhances mucus production from submucosaI glands in canine trachea in vivo
64. SRS-A leukotrienes decrease the activity of human respiratory cilia
65. Sulphidoleukotrienes in human allergic diseases
66. Effects of antihistamines in adult asthma: A meta-analysis of clinical trials
67. Arachidonic acid metabolytes: Mediators of inflammation in asthma
68. Mast cell effector mechanisms
69. A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm
70. Pharmacological modulation of leukotriene and platelet activating factor biosynthesis and activities by alternative dietary fatty acids
71. Leukotrienes and airway responses
72. 4 production in the intestine
73. Dietary fish oil and fish and borage oil suppress intrapulmonary proinflammatory eicosanoid biosynthesis and attenuate pulmonary neutrophil accumulation in endotoxic rats
74. The effects of a fish-oil-enriched diet on pulmonary mechanics during anaphylaxis
75. Enhancement of plasma levels of biologically active Ieukotriene B compounds during anaphylaxis in guinea pigs pretreated by indomethacin or by a fish oil-enriched diet
76. Dietary fish oil effects on seasonal hay fever and asthma in pollen- sensitive subjects
77. Effect of a fish oil diet on asthma: Results of a 1-year double-blind study
78. The effects of dietary supplementation with fish oil lipids on the airways response to inhaled allergen in bronchial asthma
79. 2 from snake venom, pancreas, and a macrophage-like cell line
80. Glucocorticosteroids inhibit leukotriene production
81. Inhibition of human basophil leukotriene release by antiinflammatory steroids
82. Effect of oral prednisone on airway inflammatory mediators in atopic asthma
83. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans
84. 4 in rats
85. The effect of interleukin 3 upon IgE-dependent and IgE-independent basophil degranulation and leukotriene generation
86. Selective chiral inhibitors of 5-1ipoxygenase with anti-inflammatory activity
87. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air
88. The pivotal role of 5-1ipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin
89. 4 synthase
90. 2-substituted indazolinones: Orally active and selective 5- lipoxygenase inhibitors with anti-inflammatory activity
91. Anti-inflammatory effect of YPE-01, a novel diarylheptanoid derivative, on dermal inflammation in mice
92. Pre-clinicaI pharamcology of ICI D2138, a potent orally-active non- redox inhibitor of 5-1ipoxygenase
93. 4 synthase
94. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-1ipoxygenase activating protein antagonist, BAYx 1005
95. Pharmacology of MK-0591 (3-[1-(4-chloronenzyl)-3-(t-butylthio)-5- (quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor
96. Pharmacokinetics and pharmacodynamics of multiple oral doses of MK- 0591, a 5-1ipoxygenase-activating protein inhibitor
97. A new class of leukotriene biosynthesis inhibitor: The development of MK-0591
98. Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction
99. Effect of zafirlukast (Accolate®) on airway inflammation after segmental allergen challenge in patients with mild asthma [abstract]
100. Montelukast for chronic asthma in 6- to 14-year-old children. A randomized, double-blind trial
101. Montelukast reduces airway inflammation in asthma; a randomized controlled clinical trial
102. Pharmacologic profile of SK and F 104353: A novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways
103. 4-receptor antagonism in the airways of patients with asthma
104. 4 receptor antagonist ICI 204,219
105. 4-induced bronchoconstriction in the human
106. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects
107. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: Differential sensitivity to cysteinyl leukotriene receptor antagonists
108. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
109. Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist
110. A review of its pharmacology and therapeutic potential in the management of asthma
111. 4) receptor antagonist, in patients with chronic asthma
112. Zafirlukast (Accolate) reduces the impact of asthma in patients taking inhaled corticosteroids
113. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma
114. Allergen induced late-phase airways obstruction in the pig: Mediator release and eosinophil recruitment
115. 4) receptor antagonist, on ascaris antigen-induced early and late phase airway responses in conscious squirrel monkeys [abstract]
116. The effect of montelukast (MK-0476), a cyteinyl leukotriene receptor antogonist, on allergen-induced airway response and sputum cell counts in asthma
117. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval
118. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
119. Montelukast, a Ieukotriene receptor antagonist, inhibits exercise- induced bronchoconstriction in 6- to 14- year old children [abstract]